Immunotherapy after surgery may keep early lung cancer at bay
NCT ID NCT07120282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug tislelizumab after surgery can help prevent lung cancer from coming back in people with high-risk stage I non-small cell lung cancer. About 108 adults whose tumors are 2–4 cm and have certain high-risk features will receive either tislelizumab or a placebo. The main goal is to see if the drug improves the number of patients who remain cancer-free two years after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
- New radiation technique aims to shield airways and preserve lung function
- AI assistant could help junior doctors plan lung cancer surgeries
- New drug cocktail targets Hard-to-Treat lung cancer
- App-Based breathing training aims to boost lung cancer recovery